<DOC>
	<DOCNO>NCT01948388</DOCNO>
	<brief_summary>The purpose study evaluate effect utilization two dos corticotrophin ( ACTH ) treatment patient early onset rheumatoid arthritis alternative conventional steroid therapy evaluate change baseline clinical finding well structural finding Magnetic Resonance Imaging ( MRI ) . Corticotrophin ( ACTH ) may prevent well documented structural progression damage RA patient use disease-modifying antirheumatic drug ( DMARD ) therapy alone .</brief_summary>
	<brief_title>The Effect Corticotrophin ( ACTH ) Combination With Methotrexate Newly Diagnosed Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This Phase II 24-week open-label study evaluate efficacy safety H.P . Acthar Gel Respository Injection , Corticotrophin ( ACTH ) administer newly diagnose patient rheumatoid arthritis conjunction methotrexate , folllowed 24 week follow-up period . There total twenty ( 20 ) patient two ( 2 ) treatment group 10 patient treatment group</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Patient must least 18 year old screening visit . 2 . Patient must able understand information provide give write Informed Consent . 3 . Female patient must either postmenopausal least 1 year , surgically incapable childbearing , effectively practice acceptable method contraception ( oral/parenteral/implantable hormonal contraceptive , Intrauterine Device ( IUD ) , barrier spermicide ) . Abstinence acceptable method . Patients must agree use adequate contraception study 4 week last dose corticotrophin ( ACTH ) . Male patient must agree ensure female partner ( ) use adequate contraception study 4 week patient receives last dose corticotrophin ( ACTH ) . 4 . Patients must new diagnosis adultonset rheumatoid arthritis ( RA ) define 2010 European League Against Rheumatism/American College Rheumatology ( EULAR/ACR ) classification criterion symptoms &lt; 1 year . 5 . Patients must experience mild moderate rheumatoid arthritis ( RA ) , least 6 tender 6 swollen joint screen clinical disease activity index ( CDAI ) score &gt; 6.0 6 . A Baseline Magnetic Resonance Imaging ( MRI ) must show presence osteitis erosion hand wrist . 7 . Patients must able willing comply requirement study protocol . 8 . Patients must Creactive Protein ( CRP ) erythrocyte sedimentation rate ( ESR ) &gt; upper limit normal Exclusion criterion : 1 . Patients diagnosis inflammatory arthritis ( e.g. , psoriatic arthritis ankylose spondylitis ) . 2 . Patients exposure disease modify antirheumatic drug ( DMARD ) , Biologic , Nonbiologic experimental medication treatment rheumatoid arthritis ( RA ) . 3 . Patients noninflammatory type arthritis ( e.g . osteoarthritis fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect study drug patient 's primary diagnosis rheumatoid arthritis ( RA ) . 4 . Patients history infect joint prosthesis time prosthesis still situ . 5 . Patients receive prohibited medication : nonsteroidal antiinflammatory drug ( NSAIDs /COX2 inhibitor ) ( change dose regimen 7 day prior baseline ) Oral corticosteroid within 4 week baseline Intramuscular , intravenous , intraarticular ( IM/IV/IA ) corticosteroids/ Intraarticular ( IA ) Hyaluronic acid ( dose 28 day prior baseline ) 6 . Female patient breastfeed , pregnant , plan become pregnant trial within twelve week follow last dose study drug . 7 . Patients history chronic infection due fungal , parasitic mycotic pathogen precede year , recent serious lifethreatening infection within 6 month ( include herpes zoster ) , current sign symptom may indicate infection . 8 . Patients active Tuberculosis ( TB ) ( history active TB ) , positive chest Xray TB , positive ( defined induration ≥ 5mm ) purify protein derivative ( PPD ) skin test , positive QuantiFERON , patient close contact individual active TB . Patients PPD skin test ≥ 5 mm positive QuantiFERON test enter study , provide active TB exclude provide adequately treated latent TB ( e.g. , isonicotinic acid hydrazide [ INH therapy ] 9 month [ vitamin B6 ] ) provide appropriate treatment initiate simultaneously first administration ACTH . 9 . Patients high risk infection ( e.g . leg ulcer , indwell urinary catheter persistent recurrent chest infection patient permanently bedridden wheelchair bound ) . 10 . Patients know allergy intolerance steroid 11 Concurrent malignancy history malignancy ( carcinoma cervix basal cell carcinoma successfully treat 5 year prior screen ) . 12 . Patients current recent history severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological cerebral disease . 13 . Patients class III IV congestive heart failure accord New York Heart Association ( NYHA ) 1964 classification criterion . 14 . Patients history , suspect , demyelinate disease central nervous system ( e.g . multiple sclerosis optic neuritis ) . 15 . Patients condition ( e.g . clinically significant laboratory value ) Investigator 's judgment would make patient unsuitable inclusion study . 16 . Patients metal device affect MRI ( e.g. , type electronic , mechanical , magnetic implant ; cardiac pacemaker ; aneurysm clip ( ) ; implant cardioverter defibrillator ; cochlear implant ) 17 . Patients potential ferromagnetic foreign body ( metal sliver , metal shaving , metal object ) seek medical attention . 18 . Concurrent steroid use concomitant disease . 19 . Subjects know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>